ezogabine
Sign in to saveAlso known as AWD-21360, D-23129, Potiga®, Trobalt®, WAY-143841, ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate, N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester, Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate
Retigabine (INN) or ezogabine (USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011. Production was discontinued in June 2017.
Key facts
- Drug.H
- 18
- Drug.F
- 1
- Drug.N
- 3
- Drug.O
- 2
- Drug.image
- Retigabine2DCSD.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.image2
- Retigabine ball-and-stick model from xtal 2021.png
- Drug.image_class2
- bg-transparent
- Drug.USAN
- ezogabine
- Drug.tradename
- Trobalt, Potiga
- Drug.MedlinePlus
- a612028
- Drug.licence_EU
- yes
- Drug.licence_US
- Ezogabine
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- N03
- Drug.ATC_suffix
- AX21
- Drug.legal_AU
- S4
via Wikipedia infobox
Research
485 papersvia PubMed
~7 min read
Encyclopedic overview
11 sectionsContents
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Clinical trials
- Regulatory approval
- Name
- References
- Further reading
Retigabine (INN) or ezogabine (USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011. Production was discontinued in June 2017.
Retigabine works primarily as a potassium channel opener—that is, by activating a certain family of voltage-gated potassium channels in the brain. This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including tinnitus, migraine and neuropathic pain. The manufacturer withdrew retigabine from clinical use in 2017 due to declining use, after the addition of a black box warning regarding side effects was added to the drug in 2013.
Excerpted from Wikipedia’s “ezogabine” article, available under the CC BY-SA 4.0 licence.